• Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Clinical program

    Clinical program

    10 years of development getting ready for clinical trial
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • HOME 767 310 02
  • HOME 767 310 01

About us

Arthrogen B.V., a subsidiary of MeiraGTx B.V., is an Amsterdam based biopharmaceutical company developing local gene therapy for different indications, using viral mediated gene transfer.

Technology

The therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans.

Development

It is Arthrogen’s vision that new gene therapies will contribute to the improvement of health of patients and to the reduction of healthcare cost.

Latest news

On April 29  the 22nd annual meeting of the ASGCT will start in Washington. Arthrogen will be represented by Robert Jan Lamers (CEO), Janneke Meulenberg (COO) and Sabine van der Sanden (Senior Scientist) and they are ready to make new connections! If you would like to set up a meeting, send and email to This email address is being protected from spambots. You need JavaScript enabled to view it.

Arthrogen's CEO Robert Jan Lamers is part of the Dutch delegation visiting the Global Investors Forum in Boston, held aboard the historic ship Clipper Stad Amsterdam (Pier 59, Fan Pier) on April 17th. 

 

Latest publications

Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice....

Intra-articular etanercept treatment in inflammatory arthritis...

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector...

Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02)...